Test Price
2,800 AED✅ Home Collection Available
MRPL3 Gene Genetic Test for Combined Oxidative Phosphorylation Deficiency Type 9 – Dubai, UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified NGS processing with comprehensive coding region and splice site coverage.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across Dubai and the UAE.
- Clinical Guidance: Telephonic post-test result interpretation with a board-certified consultant medical geneticist included.
- Insurance Support: Direct billing verification available via WhatsApp at +971 54 548 8731 for eligible insurance plans.
Test Overview & Methodology
This advanced next-generation sequencing (NGS) assay interrogates the entire coding region and flanking intronic boundaries of the MRPL3 gene to detect pathogenic and likely pathogenic variants associated with Combined Oxidative Phosphorylation Deficiency Type 9, a severe autosomal recessive mitochondrial disorder. The test provides definitive molecular confirmation to guide clinical management, family cascade screening, and reproductive planning.
| Feature | MRPL3 NGS Test | Single-Gene Sanger Sequencing |
|---|---|---|
| Precision | Full gene sequencing plus flanking intronic regions and CNV detection | Limited to known hotspot regions, no CNV detection |
| Method | NGS with >100x depth, bioinformatic CNV calling | Capillary electrophoresis, no CNV detection |
| Turnaround Time | 21–28 calendar days | 6–8 weeks |
Physician Insight & Safety Protocols
"Mitochondrial disorders present with highly variable clinical manifestations, and a systematic molecular approach is essential for accurate diagnosis. The MRPL3 NGS assay provides comprehensive coverage of the coding region and splice sites. A negative result does not definitively exclude a mitochondrial etiology, and further functional studies or broader genomic testing may be indicated based on the clinical presentation. Results must always be correlated with the patient's biochemical profile and phenotype."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Advisory & Safety Considerations
Patients should continue all prescribed therapies, including metabolic support regimens, without interruption during the testing period. Do not modify any treatment protocol based on preliminary or pending genetic results. Always consult with the managing specialist before making changes to therapeutic plans.
- Emergency warning: If the patient experiences metabolic crisis symptoms such as persistent vomiting, lethargy, or hypoglycemia while awaiting results, seek immediate emergency medical care. Do not rely on pending genetic test results for acute management decisions.
- Medication continuity: Genetic testing is a diagnostic tool and does not replace ongoing clinical monitoring or prescribed treatment. Never discontinue or adjust medications without direct physician guidance.
Exclusion Criteria & Procedural Restrictions
- Informed consent: Testing cannot proceed without valid informed consent. For minors, a legally authorized guardian must provide consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Recent bone marrow transplant: Patients who have undergone bone marrow transplant within the past six months are excluded due to potential donor DNA interference with germline variant detection.
- Active hematological malignancy: Individuals with active hematological malignancies that may compromise DNA extraction quality or introduce somatic variants are not suitable candidates for this germline test.
Patient FAQ & Clinical Guidance
1. What is the MRPL3 gene test and who should consider it?
The MRPL3 NGS test identifies both known and novel genetic variants in the MRPL3 gene linked to Combined Oxidative Phosphorylation Deficiency Type 9, a mitochondrial disorder affecting cellular energy production and progressively impairing multiple organ systems. Ideal candidates include infants or children presenting with unexplained lactic acidosis, developmental delay, failure to thrive, hypotonia, or multisystem involvement suggestive of mitochondrial disease. Carrier testing is also recommended for family members after identification of a proband.
2. How is the sample collected and what preparation is needed?
The test requires a peripheral blood sample (3–5 mL collected in an EDTA tube), or alternatively extracted genomic DNA or a dried blood spot on an FTA card. No fasting or medication adjustments are typically required. Our VIP mobile phlebotomy service is available daily from 8 AM to 11 PM across Dubai and the UAE. All samples are transported under ISO-certified temperature-controlled cold chain to the central laboratory. A pre-test genetic counseling session is recommended to document clinical history and construct a family pedigree.
3. How accurate is the test and what follow-up is needed after results?
The test delivers 99.9% diagnostic sensitivity for complete gene sequencing, with results interpreted by board-certified molecular geneticists. A positive result confirms the diagnosis and enables targeted management and family cascade testing. A negative result does not exclude mitochondrial disease and may prompt broader genomic re-evaluation such as mitochondrial genome sequencing or whole exome sequencing. Every patient receives a telephonic post-test consultation to explain variant classification (pathogenic, likely pathogenic, or variant of uncertain significance) and discuss implications for family members.
4. How long does it take to receive results and how are they delivered?
The standard turnaround time is 21 to 28 calendar days from sample receipt at the laboratory. Results are delivered via secure encrypted report through the patient portal and can also be emailed or printed upon request. The report includes detailed variant information, classification according to ACMG/AMP guidelines, and clinical recommendations. A telephonic consultation with a genetic counselor or the reporting physician is scheduled within 48 hours of report release.
5. Is the test covered by insurance in the UAE?
Coverage depends on your specific insurance policy and the medical necessity documented by the referring physician. We assist with direct billing verification through our insurance team, reachable via WhatsApp at +971 54 548 8731. Patients are advised to obtain pre-authorization from their insurer prior to sample collection to confirm coverage terms.
UAE Regulatory & Data Privacy Adherence
This clinical service operates in full compliance with the UAE legal framework for health data protection and laboratory practice. All patient data is handled under the provisions of Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory maintains ISO 9001:2015 certification and operates under the regulatory oversight of the Dubai Health Authority (DHA). All genetic data is stored on encrypted servers with access restricted to authorized clinical personnel only.
Results are released exclusively to the ordering physician and the patient or legal guardian following strict identity verification protocols. Data sharing with third parties requires explicit written consent from the patient, except where required by UAE law. Patients have the right to access their health data, request correction of inaccuracies, and request deletion of personal data in accordance with PDPL provisions.
Clinical & Logistical Metadata
| Test Name | MRPL3 Gene Genetic Test – Combined Oxidative Phosphorylation Deficiency Type 9 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 calendar days |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL in EDTA tube), extracted genomic DNA, or dried blood spot on FTA card |
| Methodology Used | Next-generation sequencing (NGS) with >100x depth, bioinformatic CNV calling |
| ICD-10-CM Code | E88.49 |
| LOINC Code | 94047-2 |
| DHA Facility License & Laboratory Address | License Number 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Operating under DNA Labs UAE corporate branding |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians